Finerenone Initiation, Dosing, Titration, and Monitoring in Diabetic Kidney Disease
Start finerenone at 10 mg once daily if eGFR is 25–60 mL/min/1.73 m², or 20 mg once daily if eGFR is >60 mL/min/1.73 m², after confirming serum potassium is ≤4.8 mmol/L, and uptitrate to 20 mg daily after 1 month if potassium remains ≤4.8 mmol/L and eGFR is stable. 1, 2, 3
Patient Selection Criteria
Before initiating finerenone, verify the following eligibility criteria:
- Type 2 diabetes with persistent albuminuria (UACR ≥30 mg/g) despite maximally tolerated ACE inhibitor or ARB therapy 1, 4
- eGFR ≥25 mL/min/1.73 m² (CKD stages 2–4) 1, 4
- Serum potassium ≤4.8 mmol/L at baseline 1, 2
- Already on maximum tolerated dose of RAS inhibitor (ACE inhibitor or ARB) 4, 5
Critical pitfall to avoid: Do not start finerenone before optimizing RAS inhibitor therapy—patients must be on the maximum tolerated dose of an ACE inhibitor or ARB first. 5 Starting finerenone prematurely undermines the evidence-based treatment sequence and may expose patients to unnecessary hyperkalemia risk.
Treatment Sequencing Algorithm
The evidence-based treatment hierarchy for diabetic kidney disease is:
- First-line foundation: Maximum tolerated dose of ACE inhibitor or ARB 4
- Second-line priority: SGLT2 inhibitor (larger effects on kidney and cardiovascular outcomes) 4
- Third-line consideration: Finerenone for persistent albuminuria despite SGLT2 inhibitor, or as an alternative when SGLT2 inhibitors are contraindicated or not tolerated 4, 5
The KDIGO 2022 guidelines and American College of Cardiology position finerenone as add-on therapy after RAS inhibition and, when tolerated, SGLT2 inhibitor therapy. 4, 5 However, finerenone can be used as an alternative when SGLT2 inhibitors cannot be used. 5
Initial Dosing Protocol
Dose selection is based solely on baseline eGFR:
- eGFR 25–60 mL/min/1.73 m²: Start 10 mg once daily 1, 2, 3
- eGFR >60 mL/min/1.73 m²: Start 20 mg once daily 1, 2, 3
This eGFR-based dosing strategy was used in both FIDELIO-DKD and FIGARO-DKD trials and reflects the need to balance efficacy with hyperkalemia risk in patients with more advanced kidney disease. 1, 2
Dose Titration Strategy
After 1 month of treatment, uptitrate from 10 mg to 20 mg once daily if:
- Serum potassium remains ≤4.8 mmol/L 1, 2, 3
- eGFR is stable (no significant decline) 1, 2
- The medication is well-tolerated 4
The 1-month timepoint captures the predictable initial rise in potassium that occurs with mineralocorticoid receptor antagonism and allows assessment of eGFR stability before dose escalation. 4
Potassium Monitoring Protocol
Pre-Initiation Requirements
- Verify serum potassium ≤4.8 mmol/L before starting finerenone 1, 4
- Patients with baseline potassium >4.8 mmol/L should not initiate therapy due to excessive hyperkalemia risk 4
Initial Monitoring Phase
- Check serum potassium at 1 month after starting finerenone to capture the initial potassium rise 4
Maintenance Monitoring Schedule
- Monitor serum potassium every 4 months during ongoing therapy 4
This schedule allows early detection of hyperkalemia while minimizing unnecessary testing burden. 4
Potassium-Based Management Algorithm
For potassium ≤4.8 mmol/L:
For potassium 4.9–5.5 mmol/L:
For potassium >5.5 mmol/L:
- Immediately hold finerenone 4
- Evaluate and adjust dietary potassium intake 4
- Review concomitant medications that may contribute to hyperkalemia (NSAIDs, potassium supplements, potassium-sparing diuretics) 4
- Recheck potassium levels to confirm downtrend 4
- Restart finerenone at 10 mg daily when potassium returns to ≤5.0 mmol/L 4
Critical pitfall to avoid: Do not permanently discontinue finerenone for a single episode of potassium >5.5 mmol/L unless other interventions fail. 4 Temporary interruption with dose reduction upon restart (10 mg daily) successfully manages most cases. 4
Safety Profile and Hyperkalemia Context
The pooled FIDELITY analysis (13,026 patients) demonstrated that hyperkalemia occurred in 14% of finerenone patients versus 6.9% with placebo, yet permanent discontinuation due to hyperkalemia was rare (1.7% vs 0.6%). 4, 6 No deaths were attributed to hyperkalemia in either FIDELIO-DKD or FIGARO-DKD trials over a median 3-year follow-up. 1, 5
Risk factors for hyperkalemia include:
Protective factors that reduce hyperkalemia risk:
- SGLT2 inhibitor co-administration 4
Real-world data from Japan (120 patients with DKD) confirmed that symptomatic hypotension, acute kidney injury, and hyperkalemia leading to drug discontinuation were uncommon in clinical practice. 7
Additional Monitoring Parameters
Beyond potassium, monitor:
- eGFR at baseline, 1 month, then every 4 months to assess kidney function stability 4
- UACR at baseline and month 4 to assess albuminuria response 1
- Blood pressure as finerenone causes a small reduction in systolic blood pressure 8
Clinical Benefits to Expect
Finerenone provides dual cardiorenal protection:
- 23% reduction in composite kidney outcome (kidney failure, sustained ≥57% eGFR decrease, or renal death) in the pooled FIDELITY analysis 1, 5, 6
- 14% reduction in composite cardiovascular outcome (cardiovascular death, nonfatal MI, nonfatal stroke, or heart failure hospitalization) 1, 5, 6
- 36% reduction in progression to end-stage kidney disease in FIDELIO-DKD 1, 4
- 29% reduction in heart failure hospitalizations in FIGARO-DKD 5
Real-world analysis demonstrated that finerenone significantly improved the rate of eGFR decline from -4.99 to -0.59 mL/min/1.73 m²/year (P <0.0001) and reduced UACR from 908 to 487 mg/gCr (P <0.0001). 7
Combination Therapy Considerations
Finerenone can be safely combined with SGLT2 inhibitors for complementary cardiorenal protection. 5, 9 The mechanisms are additive: SGLT2 inhibitors reduce intraglomerular pressure and provide metabolic benefits, while finerenone blocks mineralocorticoid receptor-mediated inflammation and fibrosis. 9, 8 Real-world data suggest that the eGFR slope improves regardless of whether SGLT2 inhibitor therapy is used concomitantly. 7
Do not consider SGLT2 inhibitors and finerenone interchangeable—they have complementary mechanisms and should be layered sequentially according to the treatment algorithm. 5
When NOT to Use Finerenone
Absolute contraindications:
- eGFR <25 mL/min/1.73 m² or end-stage renal disease (no established dosing or safety data) 4
- Baseline potassium >4.8 mmol/L 1, 4
- Not on maximum tolerated RAS inhibitor therapy 4, 5
Relative contraindications (trial exclusion criteria):
- Heart failure with reduced ejection fraction (excluded from FIGARO-DKD) 3
- Uncontrolled hypertension (excluded from FIGARO-DKD) 3
The landmark trials (FIDELIO-DKD and FIGARO-DKD) specifically excluded patients with eGFR <25 mL/min/1.73 m², and there is no established dosing or safety data for this population. 4